Nucleus Network

In The Know: Healthcare News for Sept. 14, 2020

Medtronic TTVR system wins breakthrough device designation Minnetronix Medical Gets FDA Clearance on Innovative Neurosurgical Access Platform FDA clears DiaSorin test that differentiates between COVID, flu Boston Scientific launches Vercise Genus DBS system in Europe Abilitech named Minne Inno’s ‘Women-led Startup of the Year’ Regulatory and Quality Solutions LLC (R&Q) Acquires Maetrics to Form the […]

Nucleus Network Begins Clinical Trial of COVID-19 Antibody Treatment

Melbourne, Australia, Friday, 11th September. Australia’s largest Phase 1 clinical trials specialist, Nucleus Network, has this week started the first human trials of a potential COVID-19 treatment developed by Singlomics (Beijing DanXu) Biopharmaceuticals and licensed by BeiGene, Ltd. Twenty-four healthy participants, aged 18 to 59 years of age, have been screened to take part this […]

In the Know: Healthcare News for September 8, 2020

CMS agrees to cover ‘breakthrough’ medical devices New Technologies Are Ushering in the Biggest Revolution in Senior Care in Over a Century University of Minnesota’s microbiology research facility key to national ‘moonshot’ effort to fight COVID FDA approves Medtronic MiniMed 770G insulin pump for young children Baxter’s dialysis filter wins De Novo nod Like Nothing […]

Nucleus Network Begins Dosing for Third COVID-19 Vaccine Trial

Melbourne, Australia, Tuesday 1st September, Australia’s largest Phase 1 Clinical trials specialist, Nucleus Network, has today commenced dosing the first human participants for the Phase 1/2 trial COVID-19 Vaccine trial in collaboration with the vaccine’s developer Serum Institute of India Pvt. Ltd in partnership with the local sponsor, Accelagen Pty Ltd. 30 healthy participants, aged […]

Nucleus Network commences Novavax’ Phase 1/2 COVID-19 vaccine trial in Australia

Melbourne, Australia, Tuesday 26th May, Australia’s largest Phase 1 Clinical trials specialist, Nucleus Network, has today commenced dosing the first human participants for the Phase 1/2 trial of NVX‑CoV2373, a SARS-CoV-2 Recombinant Spike Protein Nanoparticle vaccine, at its Melbourne clinic. Nucleus Network has begun the Phase 1/2 COVID-19 vaccine trial in Australia on behalf of […]

Keep your finger on the pulse of Medical Alley from anywhere with the ALLEY NEWSLETTER